Fairvalue-Calculator Fairvalue-Calculator
EN DE

Catalyst Pharmaceuticals, Inc (CPRX) Fair Value & Analysis

Healthcare · US · Market cap $3.8B

Price$31.40
Fair Value$38.53
Upside+22.7%
Quality95/100
Evidence: High Range $28.90 – $84.98

Fair value as of: Jun 24, 2026

Analysis

Catalyst Pharmaceuticals, Inc (CPRX) currently trades at $31.40, while our model-based Fair Value estimate is $38.53 — implying the stock looks roughly 22.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Catalyst Pharmaceuticals, Inc (CPRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $38.53 versus a price of $31.40 — about +23% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CPRX?
Our 21-model fair value for Catalyst Pharmaceuticals, Inc is $38.53 (as of Jun 24, 2026), built from audited fundamentals. The current price is $31.40.
What is the quality score of CPRX?
Catalyst Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.